Condition: MF · Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the moderate to high risk MF trial who are refractory, relapsed, or intolerant to JAK inhibitor . Select successful trial participants and allocate flonoltinib maleate tablets based on platelet count levels during the screening period, qd,Oral administration on an empty stomach until the participants meet the withdrawal criteria.
This description comes directly from the study's public registry record.
Wang Fangmei · 13808086495 · fangmei.wang@zenitar.cn
Sun Liangkun · liangkunsun@zenitar.cn
Always discuss trial participation with your own doctor first.
| West China Hospital Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS) | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07443306